Table 3.
Associations of promoter variants with antibiotic-resistance phenotypes.
| Promoter | Total no. of isolates | No. (%) of isolates with resistance toa | ||||
|---|---|---|---|---|---|---|
| AMK | GEN | TOB | SXT | CHL | ||
| Total | 96 | 12 (12.5) | 51 (53.1) | 39 (40.6) | 69 (71.9) | 39 (40.6) |
| Strong promoter | 47 | 12 (25.5) | 38 (82.8) | 37 (78.7) | 37 (78.7) | 17 (36.2) |
| PcWTGN-10 | 7 | 1 (14.3) | 5 (71.4) | 5 (71.4) | 6 (85.7) | 1 (14.3) |
| PcS | 40 | 11 (27.5) | 33 (85.2) | 32 (80) | 31 (77.5) | 16 (40) |
| MIC50 (μg/ml) | ≤ 2 | ≥ 16 | ≥16 | ≥ 16 | ≥64 | |
| Weak promoter | 49 | 0 (0) | 13 (26.5) | 2 (4.1) | 32 (65.3) | 22 (44.9) |
| PcH1 | 49 | 0 (0) | 13 (26.5) | 2 (4.1) | 32 (65.3) | 22 (44.9) |
| MIC50 (μg/ml) | – | ≤ 4 | ≤4 | ≥ 16 | 16 | |
| p-valueb | 0.000 | 0.000 | 0.000 | 0.144 | 0.384 | |
aAMK amikacin, GEN gentamicin, TOB tobramycin, SXT Trimethoprim/Sulfamethoxazole, CHL chloramphenicol bThe chi-squared test was used to assess strong promoter and weak promoters.